Université de Nantes, CHU Nantes, CNRS, INSERM, l'institut du thorax, F-44000 Nantes, France.
InFlectis BioScience, Nantes, France.
Oxid Med Cell Longev. 2020 Dec 24;2020:6681073. doi: 10.1155/2020/6681073. eCollection 2020.
Septic shock is a systemic inflammatory response syndrome associated with circulatory failure leading to organ failure with a 40% mortality rate. Early diagnosis and prognosis of septic shock are necessary for specific and timely treatment. However, no predictive biomarker is available. In recent years, improvements in proteomics-based mass spectrometry have improved the detection of such biomarkers. This approach can be performed on different samples such as tissue or biological fluids. Working directly from human samples is complicated owing to interindividual variability. Indeed, patients are admitted at different stages of disease development and with signs of varying severity from one patient to another. All of these elements interfere with the identification of early, sensitive, and specific septic shock biomarkers. For these reasons, animal models of sepsis, although imperfect, are used to control the kinetics of the development of the pathology and to standardise experimentation, facilitating the identification of potential biomarkers. These elements underline the importance of the choice of animal model used and the sample to be studied during preclinical studies. The aim of this review is to discuss the relevance of different approaches to enable the identification of biomarkers that could indirectly be relevant to the clinical setting.
感染性休克是一种全身性炎症反应综合征，与循环衰竭相关，可导致多器官功能衰竭，死亡率为 40%。早期诊断和预后感染性休克对于特定和及时的治疗是必要的。然而，目前还没有预测性的生物标志物。近年来，基于蛋白质组学的质谱分析技术的改进提高了这些生物标志物的检测能力。这种方法可以在不同的样本上进行，如组织或生物流体。由于个体间的差异，直接从人体样本中进行分析是复杂的。事实上，患者在疾病发展的不同阶段入院，并且从一个患者到另一个患者的严重程度不同。所有这些因素都干扰了早期、敏感和特异性感染性休克生物标志物的识别。出于这些原因，尽管并不完美，但是使用败血症动物模型来控制病理学发展的动力学，并使实验标准化，以促进潜在生物标志物的识别。这些因素强调了在临床前研究中选择使用的动物模型和要研究的样本的重要性。本文的目的是讨论不同方法的相关性，以确定可能与临床相关的间接生物标志物。
